A Phase I Study To Evaluate The Safety, Tolerability, Immunogenicity, Pharmacokinetics And Pharmacodynamics Of Escalating Doses Of RN564 In Women With Osteopenia And In Healthy Men.
Phase of Trial: Phase I
Latest Information Update: 21 Jun 2012
At a glance
- Drugs RN 564 (Primary)
- Indications Metabolic bone diseases; Osteoporosis
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 21 Jun 2012 Actual end date May 2012 added as reported by ClinicalTrials.gov.
- 21 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.